The impact of statin treatment on diabetic patients

Current Opinion in Investigational Drugs

Volumn 4, Issue 4, 2003, Pages 395-400

  Koshiyama, Hiroyuki ^a  

^a Kitano Hospital   (Japan)

Author keywords

Atherosclerosis; Diabetes; Endothelial dysfunction; LDL cholesterol; Macrovascular disease; Pleiotropic action; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PLEIOTROPY; POLYNEUROPATHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; STROKE; SUICIDE; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; VIOLENCE;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; RISK FACTORS;

EID: 0038206674     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care (2002) 25(Suppl 1):S74-S77. This paper describes the ADA's recommendation of the treatment goal for dyslipidemia associated with diabetes. The optimal LDL-C is less than 100 mg/dl, irrespective of the presence or absence of atherosclerotic diseases.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention trial. Diabetes Care (1993) 16(2):434-444.
3. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study. Br Med J (1983) 287(6396):867-870.
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352(9131):837-853.
5. Kosmiski LA, Eckel RH: Dyslipidemia in noninsulin-dependent diabetes mellitus. In: Clinical Research in Diabetes and Obesity. Draznin B, Rizza R (Eds), Humana Press, New York, NY, USA (1997):159-185.
6. Ginsberg HN, Tuck C: Diabetes and dyslipidemia. In: Diabetes and Cardiovascular Disease. Johnstone MT, Veves A (Eds), Humana Press, New York, NY, USA (2001):131-147.
7. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: The Framingham study. Circulation (1979) 59(1):8-13.
8. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br Med J (1998) 316(7134):823-828.
9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 339(4):229-234. This Finnish study indicates that the incidence of MI in diabetic patients without diagnosed CHD was similar to that for non-diabetic individuals who had experienced an MI.
10. Steiner G: Lipid intervention trials in diabetes. Diabetes Care (2000) 23(Suppl 2):B49-B53. A brief review of clinical trials of lipid-lowering therapy and CHD. The study designs are also described.
11. Kreisberg RA, Oberman A: Clinical review 141: Lipids and atherosclerosis: Lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab (2002) 87(2):423-427. A review of clinical trials of lipid-lowering therapy. The pleiotropic actions and safety of statins are discussed. The significance of several lipid trials is specifically described in relation to diabetes mellitus.
12. Pyörälä L, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (1997) 20(4):614-620. The post hoc subgroup analysis of the 4S study suggests that simvastatin treatment improves the prognosis of diabetic patients with CHD and that absolute risk reduction in diabetic patients is greater than that in non-diabetic individuals.
13. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation (1998) 98(23):2513-2519. The subanalysis of the CARE trial suggests that pravastatin treatment reduces the CHD event in diabetic patients, who are at greater absolute risk than non-diabetic individuals.
14. The Long-term Intervention with Pravastatin Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol group. N Engl J Med (1998) 339(19):1349-1357. The LIPID trial indicates that the absolute benefits of pravastatin treatment are greater in groups with lower levels of HDL cholesterol, older age or a history of diabetes or smoking.
15. Steiner G: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet (2001) 357(9260):905-910.
16. Hebert PR, Gaziano JM, Chan KS, Hennekens CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc (1997) 278(4):313-321.
17. Crouse JR III, Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med (1997) 157(12):1305-1310.
18. Chiquette E, Chilton R: Cardiovascular disease: Much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep (2002) 4(2):134-142.
19. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet (2002) 360(9326):7-22.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc (2001) 285(19):2486-2497. ATP III is an updated guideline from the NCEP. Diabetes is treated as equivalent in risk to CHD, with an LDL goal of < 100 mg/dl.
21. Grundy SM: United States cholesterol guidelines 2001: Expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol (2001) 88(7B):23J-27J.
22. Santiago JM, Dalen JE: Cholesterol and violent behavior. Arch Intern Med (1994) 154(12):1317-1321.
23. Manfredini R, Caracciolo S, Salmi R, Boari B, Tomelli A, Gallerani M: The association of low serum cholesterol with depression and suicidal behaviours: New hypotheses for the misisng link. J Int Med Res (2000) 28(6):247-257.
24. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J et al: Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol (2000) 86(3):257-262.
25. Simes J: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet (2002) 359(9315):1379-1387.
26. Gaist D, Jeppesen U, Andersen M, Garcia-Rodríguez LA, Hallas J, Sindrup SH: Statins and risk of polyneuropathy: A case-control study. Neurology (2002) 58(9):1333-1337.
27. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol (2001) 21(11):1712-1719. A brief review of pleiotropic effects of statins. Many of these effects are related to inhibition of synthesis of small GTPases.
28. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 13(4):581-589.
29. Wassmann S, Laufs U, Müller K, Konkol C, Ahlbory K, Bäumer AT, Linz W, Böhm M, Nickenig G: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol (2002) 22(2):300-305.
30. Wassmann S, Laufs U, Bäumer AT, Müller K, Ahlbory K, Linz W, Itter G, Rösen R, Böhm M, Nickenig G: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 37(6):1450-1457.
31. Essig M, Nguyen G, Prié D, Escoubet B, Sraer J-D, Friedlander G: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res (1998) 83(7):683-690.
32. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 6(9):1004-1010.
33. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest (2001) 108(3):391-397.
34. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest (2001) 108(3):399-405.
35. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett (2001) 495(3):159-166.
36. klp21. J Biol Chem (1999) 274(3):21926-21931.
37. phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci (2000) 67(8):863-876.
38. Klein RL, Colwell JA: Altered endothelial function in diabetes mellitus: An overview. In: Endocrinology of the Vasculature. Sowers JR (Ed), Humana Press, Totowa, NJ, USA (1996):125-134.
39. Johnstone MT, Caulfield TA: Nitric oxide and its role in diabetes mellitus. In: Diabetes and Cardiovascular Disease. Draznin B, Rizza R (Eds), Humana Press, Totowa, NJ, USA (1997):213-236.
40. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, Egashira K, Iguchi A: Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation (2001) 104(4):376-379.
41. Van Etten RW, De Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ: Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol (2002) 22(5):799-804.
42. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286(5446):1946-1949.
43. Chung Y-S, Lee M-D, Lee S-K, Kim H-M, Fitzpatrick LA: HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab (2000) 85(3):1137-1142.
44. Wada Y, Nakamura Y, Koshiyama H: Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med (2000) 160(18):2865.
45. Koshiyama H, Wada Y, Nakamura Y: Hypercholesterolemia as a possible risk factor for osteopenia in type 2 diabetes. Arch Intern Med (2001) 161(13):1678.
46. Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M, Demer LL: Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res (1999) 14(12):2067-2078.
47. Parhami F, Tintut Y, Beamer WG, Gharavi N, Goodman W, Demer LL: Atherogenic high-fat diet reduces bone mineralization in mice. J Bone Miner Res (2001) 16(1):182-188.
48. Freeman DJ, Norrie J, Sattar N, Neely RDG, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ et al: Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 103(3):357-362. The post hoc analysis of WOSCOPS revealed that pravastatin treatment resulted in a 30% reduction in the risk of developing diabetes.
49. Stern MP: Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes (1995) 44(4):369-374.
50. Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K: Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study Group. Diabetes Care (1999) 22(11):1771-1778.
51. Grover SA, Coupal L, Zowall H, Dorais M: Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation (2000) 102(7):722-727.
52. Pitt B, Waters D, Brown WV, Van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med (1999) 341(2):70-76.
53. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. J Am Med Assoc (2001) 285(13):1711-1718.
54. Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol (2001) 88(5):504-508.
55. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Ogawa N, Goto Y: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162(2):373-379.
56. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H: Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation (1998) 97(18):1784-1790.
57. Smilde TJ, Van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomized, double-blinded trial. Lancet (2001) 357(9256):577-581.
58. Koshiyama H, TanakaS, Minamikawa J: Effect of calcium channel blocker amlodipine on the intimal-medial thickness of carotid artery in type 2 diabetes. J Cardiovasc Pharmacol (1999) 33(6):894-896.
59. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y: Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab (2001) 86(7):3452-3456.
60. Waters DD: Early pharmacologic intervention and plaque stability in acute coronary syndromes. Am J Cardiol (2001) 88(8A):30K-36K.